Latest News

John Krystal, MD, Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry, of Neuroscience, and of Psychology; and Irina Esterlis, PhD, associate professor of psychiatry, are first and senior authors, respectively, of a review published in Proceedings of the National Academy of Sciences Perspective that considers what scientists have learned from studies of ketamine and to suggest future directions for the optimization of rapid-acting antidepressant treatment.

Sophie Holmes, PhD, assistant professor of psychiatry, told National Geographic that continued research is needed to determine who might benefit from being treated by ketamine, the drug often prescribed in cases of severe depression and anxiety.

Samuel Wilkinson, MD, associate professor of psychiatry, and Greg Rhee, PhD, assistant professor adjunct of psychiatry, have been awarded two grants through the National Institutes of Health Research Project Grants Program.

In this CNN Health story, a mother talks about her fears of losing her son to treatment-resistant depression, and a doctor's suggestion to try a medication off-label changed everything. YCSC Associate Professor Michael Bloch addresses some factors around ketamine treatment and research.

Sina Nikayin, MD, assistant professor of psychiatry, and Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, are co-authors of a viewpoint in JAMA Psychiatry that explores how expectations influence outcomes of psychedelic drug therapy.

Or Duek, PhD, assistant professor adjunct of psychiatry, and Ilan Harpaz-Rotem, PhD, professor of psychiatry and of psychology, are first and senior authors, respectively of a study published in Neuropsychopharmacology that tests the potential of a single infusion of ketamine, followed by brief exposure therapy, to enhance post-retrieval extinction of post-traumatic stress disorder trauma memories.

Off-label, unsupervised use of ketamine has skyrocketed since regulatory changes were put in place at the height of the COVID pandemic. Yale psychiatrist Gerard Sanacora, a worldleader in ketamine research and clinical use, discusses some of the risks patients may be taking.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Sophie Holmes, PhD, assistant professor of psychiatry, Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, and Sophie Holmes, PhD, assistant professor of psychiatry, spoke about depression and mental health in Parkinson’s disease, as well as how ketamine can treat depression, on the Trembling EMT Podcast.

Gerard Sanacora, MD, PhD, George D. and Esther S. Gross Professor of Psychiatry, spoke to Medscape about the effort to create a ketamine registry to collect data on dosage, treatment frequency, adverse events, and long-term outcomes in patients receiving the therapy for depression and other mental health conditions.